Neurology Medical News about Sumatriptan Pregnancy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?
Headache: The Journal of Head and Face Pain, 10/07/09

Cunnington M et al. – The risk of all major birth defects following first–trimester exposure to sumatriptan was 4.6% (95% CI 2.9–7.2%). This coupled with a consistent failure of additional epidemiological studies to observe a signal for major teratogenicity gives a level of reassurance concerning the safety of sumatriptan in pregnancy. There are too few data on naratriptan to draw definitive conclusions, and the sample size for sumatriptan remains too small to detect any but very large increases in specific birth defects.

<< Previous
Prolactinoma in Children and Adolescents

Next >>
Ankle-Brachial Index, a Screening for Peripheral Obstructive...